Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9451907 | 0.82 | RECQL (0.40) | — | |
| SCHEMBL9451955 | 0.80 | CHRM2 (0.46) | MAPTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL10699712 | 0.78 | ALDH1A1 (0.43) | SMN1; SMN2LMNA | |
| SCHEMBL10698234 | 0.78 | MAPT (0.44) | MAPTSMN1; SMN2TDP1LMNAADRA2A | |
| SCHEMBL9451962 | 0.78 | LMNA (0.35) | LMNA | |
| SCHEMBL10697362 | 0.78 | KDM4E (0.43) | MAPTSMN1; SMN2LMNA | |
| SCHEMBL9451944 | 0.77 | — | — | |
| SCHEMBL9835542 | 0.76 | MEN1 (0.45) | MAPT | |
| SCHEMBL9728521 | 0.75 | MAPT (0.41) | MAPTLMNAADRA2ADRD2ADRA2B | |
| SCHEMBL9833493 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0234011-B1 | 4-(1,2,5,6-TETRAHYDRO-1-ALKYL-3-PYRIDINYL)-2-THIAZOLAMINES AND 4-(HEXAHYDRO-1-ALKYL-3-PYRIDINYL)-2-THIAZOLAMINES | WARNER-LAMBERT COMPANY (US) | 1991-09-18 | — | — | EP | claimed |
| US-4650805-A | 4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines and 4-(hexahydro-1-alkyl-3-pyridinyl)-2-thiazolamines having anti-psychotic activity | WARNER-LAMBERT COMPANY (US) | 1987-03-17 | — | — | US | claimed |
| US-20140275224-A1 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-09-18 | — | — | US | disclosed |
| EP-2635280-A2 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | Regents of the University of Minnesota (US) | 2013-09-11 | — | — | EP | disclosed |
| WO-2013074059-A2 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-05-23 | — | — | WO | disclosed |
| US-7776833-B2 | Use of cyclic bioisosters of purine system derivatives for treating diseases produced by disorders of niterergic and dopaminergic systems | Zhilov, Valery Khazhmuratovich (RU) | 2010-08-17 | — | — | US | disclosed |
| EP-2074998-A2 | Use of cyclic bioisosteres of purine system derivatives for the treatment of diseases caused by disorders of nitrergic and dopaminergic systems | Zhilov, Valery Khazhmuratovich (RU) | 2009-07-01 | — | — | EP | disclosed |
| EP-1655028-B1 | USE OF CYCLIC BIOISOSTERES OF PURINE SYSTEM DERIVATIVES FOR THE TREATMENT OF DISEASES CAUSED BY DISORDERS OF NITRERGIC AND DOPAMINERGIC SYSTEMS | ZHILOV VALERY KHAZHMURATOVICH (RU) | 2009-05-13 | — | — | EP | disclosed |
| US-20070135636-A1 | Use of cyclic bioisosters of purine system derivatives for treating diseases produced by disorders of niterergic and dopaminergic systems | VALERY KHAZHMURATOVICH ZHILOV (RU) | 2007-06-14 | — | — | US | disclosed |
| EP-1655028-A2 | USE OF CYCLIC BIOISOSTERES OF PURINE SYSTEM DERIVATIVES FOR THE TREATMENT OF DISEASES CAUSED BY DISORDERS OF NITRERGIC AND DOPAMINERGIC SYSTEMS | Zhilov, Valery Khazhmuratovich (RU) | 2006-05-10 | — | — | EP | disclosed |
| EP-0234011-B1 | 4-(1,2,5,6-TETRAHYDRO-1-ALKYL-3-PYRIDINYL)-2-THIAZOLAMINES AND 4-(HEXAHYDRO-1-ALKYL-3-PYRIDINYL)-2-THIAZOLAMINES | WARNER-LAMBERT COMPANY (US) | 1991-09-18 | — | — | EP | disclosed |
| US-4739067-A | NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS, HYPOTENSIVE AGENT, HORMONE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1988-04-19 | — | — | US | disclosed |
| US-4739067-A | NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS, HYPOTENSIVE AGENT, HORMONE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1988-04-19 | — | — | US | disclosed |
| US-4739067-A | NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS, HYPOTENSIVE AGENT, HORMONE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1988-04-19 | — | — | US | disclosed |
| EP-0234011-A1 | 4-(1,2,5,6-tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines and 4-(hexahydro-1-alkyl-3-pyridinyl)-2-thiazolamines | WARNER-LAMBERT COMPANY (US) | 1987-09-02 | — | — | EP | disclosed |
| EP-0234011-A1 | 4-(1,2,5,6-tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines and 4-(hexahydro-1-alkyl-3-pyridinyl)-2-thiazolamines | WARNER-LAMBERT COMPANY (US) | 1987-09-02 | — | — | EP | disclosed |
| EP-0234011-A1 | 4-(1,2,5,6-tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines and 4-(hexahydro-1-alkyl-3-pyridinyl)-2-thiazolamines | WARNER-LAMBERT COMPANY (US) | 1987-09-02 | — | — | EP | disclosed |
| US-4650805-A | 4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines and 4-(hexahydro-1-alkyl-3-pyridinyl)-2-thiazolamines having anti-psychotic activity | WARNER-LAMBERT COMPANY (US) | 1987-03-17 | — | — | US | disclosed |
| US-4650805-A | 4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines and 4-(hexahydro-1-alkyl-3-pyridinyl)-2-thiazolamines having anti-psychotic activity | WARNER-LAMBERT COMPANY (US) | 1987-03-17 | — | — | US | disclosed |
| US-4650805-A | 4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines and 4-(hexahydro-1-alkyl-3-pyridinyl)-2-thiazolamines having anti-psychotic activity | WARNER-LAMBERT COMPANY (US) | 1987-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135636-A1 | Use of cyclic bioisosters of purine system derivatives for treating diseases produced by disorders of niterergic and dopaminergic systems | ADORA2A, ADORA3, ADORA1 | MAPT 1864/4885SMN1; SMN2 1312/4885TDP1 255/4885 |
| US-20140275224-A1 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | CDA, DCTD, ADA | MAPT 4829/4885SMN1; SMN2 2561/4885TDP1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.